ADAndreas P. Diamantopoulos

Andreas P. Diamantopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas P. Diamantopoulos has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Updates on giant cell arteritis: pathogenesis, diagnosis and treatment, volume II

    by Andreas P. Diamantopoulos, Stavros Chrysidis

    The role of temporal artery biopsy (TAB), while debated, remains pivotal in diagnosing cranial GCA. Stamatis et al. (2024) underscore its continued importance despite the rise of imaging techniques such as ultrasound (US) and Positron Emission Tomography (PET). TAB has high specificity for cranial GCA, though its sensitivity can vary, particularly in patients with large-vessel GCA (LV-GCA). Specimen length, number of sections, and biopsy timing (preferably within two weeks of starting glucocorticoids) influence TAB's diagnostic yield.Although imaging techniques have improved, Stamatis et al. underscore that TAB is essential for differentiating healed arteritis from age-related atherosclerosis, which can be diagnostically challenging. Thus, TAB continues to play a role in diagnosing cranial GCA, especially when imaging results are unclear.US has emerged as a noninvasive alternative to TAB for diagnosing GCA, mainly through the halo sign, which may indicate temporal artery inflammation. In a landmark study by Haaversen et al. (2024), ultrasound was critical for diagnosis and follow-up, though its sensitivity for relapse detection was only 61.2%. To improve monitoring, Haaversen introduced the GCA Activity Score (GCAS), which integrates ultrasound, clinical symptoms, and inflammatory markers like CRP, proving helpful in detecting subclinical relapses. PET and Magnetic Resonance Imaging (MRI) have demonstrated value in identifying LV-GCA, where inflammation extends beyond cranial vessels. Gorlen et al. (2024) showed that PET is particularly effective for excluding malignancies in patients with suspected polymyalgia rheumatica (PMR) or GCA.A retrospective cohort study by Andel et al. (2023) using the updated 2022 ACR/EULAR classification criteria found that mixed-GCA (cranial and large-vessel involvement) was the most common phenotype, supporting the use of advanced imaging to identify and classify GCA subtypes more effectively.GCA presents with diverse clinical phenotypes, complicating the diagnostic process. The classic cranial GCA is characterized by headache, jaw claudication, and vision problems, while LV-GCA manifests more subtly, with systemic symptoms like fever and weight loss. Skaug et al. (2023) found that patients with non-cranial GCA experienced longer diagnostic delays than those with cranial involvement.These findings suggest the importance of regularly imaging non-cranial arteries in suspected GCA cases, especially in younger patients, to avoid diagnostic delays. Given that non-cranial GCA patients are often underdiagnosed, prompt imaging can reduce the risk of complications such as aortic aneurysms and stroke, as supported by Ayo-Martin et al. (2023), who found that vertebral vasculitis is significantly associated with increased stroke risk.Relapses in GCA remain a primary clinical concern, with rates as high as 60.6%, as Haaversen et al. ( 2024)noted. Contrary to earlier beliefs, relapses occur at similar rates across cranial, large-vessel, and mixed subtypes, underscoring the need for consistent monitoring.The GCA Activity Score (GCAS), which combines clinical, biochemical, and imaging data, has emerged as an essential tool for identifying subclinical relapses that might otherwise go undetected.In cases where ultrasound is inconclusive, Monti et al. ( 2023) highlight the complementary value of PET and MRI, particularly for monitoring large-vessel involvement. These imaging techniques are essential in capturing ongoing inflammation in patients who remain asymptomatic yet have active disease.Complications from untreated or inadequately managed GCA can be severe, including sight loss, stroke, and aortic aneurysms. Ayo-Martin et al. ( 2023) introduced a novel method of using vertebral artery diameter measured via ultrasound to indicate vertebral vasculitis, which is associated with an increased risk of stroke. 2023) also highlighted traditional cardiovascular risk factors such as age, smoking, and hypertension as the strongest predictors of mortality in GCA patients.Interestingly, their long-term study found no significant increase in cancer incidence among GCA patients, suggesting that routine cancer screening may not be necessary.Beyond its physical complications, GCA imposes a significant psychological burden. In a cross-sectional study by Froehlich et al. ( 2023), 40% of GCA patients were found to suffer from major depressive disorder. The study also found a strong correlation between elevated CRP levels and depressive symptoms, suggesting that systemic inflammation may contribute to mental health impairment in GCA patients. These findings underscore the importance of integrating mental health assessments into the routine care of GCA patients, especially considering the potential link between inflammatory markers and psychological distress.While glucocorticoids remain the cornerstone of GCA treatment, their long-term use is associated with significant side effects, including osteoporosis, diabetes, and increased infection risk. Biologic therapies, such as tocilizumab, offer a targeted approach to reducing inflammation while sparing patients from glucocorticoid-related side effects. Pankow et al.(2023) reported promising results using mycophenolate mofetil (MMF) as a steroid-sparing therapy for GCA, significantly reducing CRP levels and disease remission in a small cohort.These findings pave the way for future randomized controlled trials to establish MMF's role in the broader treatment landscape for GCA.In addition, glucocorticoids reduce the sensitivity of various diagnostic methods. Stamatis et al. (2024) emphasize that TAB should ideally be performed before initiating glucocorticoids to preserve diagnostic accuracy.GCA remains a complex condition that requires a dynamic approach to diagnosis and management. The combined use of advanced imaging and the GCAS represents a significant step forward in diagnosing, monitoring, and managing GCA. Haaversen et al. (2024) and...


  • Open Access

    Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis

    by Anne Bull Haaversen, Lene Kristin Brekke, Gunnstein Bakland, Erik Rødevand, Geirmund Myklebust, Andreas P. Diamantopoulos

    Objective: To provide clinical guidance to Norwegian Rheumatologists and other clinicians involved in diagnosing and treating patients with giant cell arteritis (GCA).Methods: The available evidence in the field was reviewed, and the GCA working group wrote draft guidelines. These guidelines were discussed and revised according to standard procedures within the Norwegian Society of Rheumatology. The European Alliance of Associations for Rheumatology (EULAR) recommendations for imaging and treatment in large vessel vasculitis and the British Society for Rheumatology (BSR) guidelines for diagnostics and treatment in GCA informed the development of the current guidelines.Results: A total of 13 recommendations were developed. Ultrasound is recommended as the primary diagnostic test. In patients with suspected GCA, treatment with high doses of Prednisolone (40–60 mg) should be initiated immediately. For patients with refractory disease or relapse, Methotrexate (MTX) should be used as the first-line adjunctive therapy, followed by tocilizumab (TCZ).Conclusion: Norwegian recommendations for diagnostics and treatment to improve management and outcome in patients with GCA were developed.


  • Open Access

    Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis—A Pilot Study

    by Maja Stojanovic, Sanvila Raskovic, Vladimir Milivojevic, Rada Miskovic, Ivan Soldatovic, Sanja Stankovic, Ivan Rankovic, Marija Stankovic Stanojevic, Sanja Dragasevic, Miodrag Krstic, et al.

    Takayasu Arteritis (TA) is characterized by granulomatous panarteritis, vessel wall fibrosis, and irreversible vascular impairment. The aim of this study is to explore the usefulness of the Enhanced Liver Fibrosis score (ELF), procollagen-III aminoterminal propeptide (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and hyaluronic acid (HA) in assessing vascular damage in TA patients. ELF, PIIINP, TIMP-1, and HA were measured in 24 TA patients, and the results were correlated with the clinical damage indexes (VDI and TADS), an imaging damage score (CARDS), and disease activity scores (NIH and ITAS2010). A mean ELF score 8.42 (±1.12) and values higher than 7.7 (cut-off for liver fibrosis) in 21/24 (87.5%) of patients were detected. The VDI and TADS correlated significantly to ELF (p < 0.01). Additionally, a strong association across ELF and CARDS (p < 0.0001), PIIINP and CARDS (p < 0.001), and HA and CARDS (p < 0.001) was observed. No correlations of the tested biomarkers with inflammatory parameters, NIH, and ITAS2010 scores were found. To our knowledge, this is the first study that suggests the association of the serum biomarkers PIIINP, HA, and ELF score with damage but not with disease activity in TA patients. The ELF score and PIIINP may be useful biomarkers reflecting an ongoing fibrotic process and quantifying vascular damage.


  • Open Access

    Survival and death causes of patients with giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study

    by L. K. Brekke, B.-T. S. Fevang, A. P. Diamantopoulos, J. Assmus, E. Esperø, C. G. Gjesdal

    Our objective was to determine the survival and causes of death in a large and well-characterized cohort of patients with giant cell arteritis (GCA). This is a hospital-based, retrospective, observational cohort study including patients diagnosed with GCA in Western Norway during 1972–2012. Patients were identified through computerized hospital records using the International Classification of Diseases (ICD)-coding system. Medical records were reviewed. Patients were randomly assigned population controls matched on age, sex, and geography from the Central Population Registry of Norway (CPRN). Date and cause of death were obtained from the Norwegian Cause of Death Registry (NCoDR). The survival was analyzed using Kaplan-Meier methods with the Gehan-Breslow test and the causes of death using cumulative incidence and Cox models for competing risks. We identified 881 cases with a clinical diagnosis of GCA of which 792 fulfilled the American College of Rheumatology (ACR) 1990 classification criteria. Among those fulfilling the ACR criteria, 528 were also biopsy-verified. Cases were matched with 2577 population controls. A total of 490 (56%) GCA patients and 1517 (59%) controls died during the study period. We found no difference in the overall survival of GCA patients compared to controls, p = 0.413. The most frequent underlying causes of death in both groups were diseases of the circulatory system followed by cancer. GCA patients had increased risk of dying of circulatory disease (HR 1.31, 95% CI 1.13–1.51, p < 0.001) but lower risk of dying of cancer (HR 0.56, 95% CI 0.42–0.73, p < 0.001) compared to population controls. We found no difference in the overall survival of GCA patients compared to matched controls, but there were differences in the distribution of underlying death causes.


  • Open Access

    Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study

    by L. K. Brekke, A. P. Diamantopoulos, B-T. Fevang, J. Aβmus, E. Esperø, C. G. Gjesdal

    Giant cell arteritis (GCA) is the most common systemic vasculitis in persons older than 50 years. The highest incidence rates of the disease have been reported in Scandinavian countries. Our objective was to determine the epidemiology of GCA in an expected high-incidence region during a 41-year period. This is a hospital-based, retrospective, cohort study. Patients diagnosed with GCA in Bergen health area during 1972–2012 were identified through computerized hospital records (n = 1341). Clinical information was extracted from patients’ medical journals, which were reviewed by a standardized method. We excluded patients if data were unavailable (n = 253), if the reviewing rheumatologist found GCA to be an implausible diagnosis (n = 207) or if the American College of Rheumatology (ACR) 1990 classification criteria for GCA were not fulfilled (n = 89). Descriptive methods were used to characterize the sample. Incidence was analyzed by graphical methods and Poisson regression. A total of 792 patients were included. The average annual cumulative incidence of GCA was 16.7 (95% CI 15.5-18.0) per 100,000 of the population ≥ 50 years old. The corresponding incidence for biopsy-verified GCA was 11.2 (95% CI 10.2–12.3). The annual cumulative incidence increased with time in the period 1972–1992 (relative risk (RR) 1.1, p < 0.001) but not in 1993–2012 (RR 1.0, p = 0.543). The incidence was higher in women compared to men (average annual incidence 37.7 (95% CI 35.8–39.6) vs. 14.3 (95% CI 13.2–15.5), p < 0.001) with women having a twofold to threefold higher incidence rate throughout the study period. Average annual incidence increased with age until the 7th decade of life in both sexes throughout the study period (2.8 (95% CI 2.3–3.3) for age <60, 15.5 (95% CI 14.4–16.8) for age 60–69, 34.5 (95% CI 32.8–36.4) for age 70–79 and 26.8 (95% CI 25.3-28.4) for age ≥80 years, p < 0.001 for all age adjustments). Our study confirms an incidence of GCA comparable to previous reports on Scandinavian populations. Our results show increasing incidence from 1972 through 1992, after which the incidence has levelled out.


  • Open Access

    Settings and artefacts relevant for Doppler ultrasound in large vessel vasculitis

    by L. Terslev, A. P. Diamantopoulos, U. Møller Døhn, W. A. Schmidt, S. Torp-Pedersen

    Ultrasound is used increasingly for diagnosing large vessel vasculitis (LVV). The application of Doppler in LVV is very different from in arthritic conditions. This paper aims to explain the most important Doppler parameters, including spectral Doppler, and how the settings differ from those used in arthritic conditions and provide recommendations for optimal adjustments. This is addressed through relevant Doppler physics, focusing, for example, on the Doppler shift equation and how angle correction ensures correctly displayed blood velocity. Recommendations for optimal settings are given, focusing especially on pulse repetition frequency (PRF), gain and Doppler frequency and how they impact on detection of flow. Doppler artefacts are inherent and may be affected by the adjustment of settings. The most important artefacts to be aware of, and to be able to eliminate or minimize, are random noise and blooming, aliasing and motion artefacts. Random noise and blooming artefacts can be eliminated by lowering the Doppler gain. Aliasing and motion artefacts occur when the PRF is set too low, and correct adjustment of the PRF is crucial. Some artefacts, like mirror and reverberation artefacts, cannot be eliminated and should therefore be recognised when they occur. The commonly encountered artefacts, their importance for image interpretation and how to adjust Doppler setting in order to eliminate or minimize them are explained thoroughly with imaging examples in this review.